There are a lot of new payment and delivery models available and being tested, but the US still doesn’t have a payment system that aligns people’s incentives the right way, said Margaret E. O’Kane. Instead, with fee-for-service around, people still have an incentive for overuse, because they can make money.
Watching the new payment and delivery models, though, she pointed out that it’s important to not just get caught up on whether a certain model work. That’s not the right mindset. Instead, people should choose a model and make it work by adjusting it until payment policies are in place to reward efficiency.
Matt Salo added that while it’s great to consider shared savings or bundled payments, they need to be paired with the right tools to make them work. He used the example that primary care physicians need to be shown how to set up a patient-centered medical home, how to structure it, who to hire, etc.
He tied the conversation into patient engagement in new delivery models and figuring out what motivates the patient and why, for instance, are families overusing the emergency room.
“You’ve got to figure out why are they doing what they’re doing that’s wrong, and how do you empower them to do the right thing,” Salo said.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More